Teva Pharmaceutical Industries reported its second-quarter 2025 financial results on Wednesday, reflecting a mixed performance amid continued shifts in its portfolio strategy. CEO Richard Francis speaks with Bloomberg's Scarlet Fu and Katie Griefeld.

IMF Chief Kristalina Georgieva Talks US Economy, Kevin Warsh
13:44

Affirm CEO Max Levchin Talks Revenue Growth, Consumer Spending
07:54

Harvard's Ken Rogoff Talks US Debt, Fiscal Crisis Risks
07:36